Loading...
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
OBJECTIVE: Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was to investigate the long-term safety of LESU...
Saved in:
| Published in: | Rheumatology (Oxford) |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Oxford University Press
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6293483/ https://ncbi.nlm.nih.gov/pubmed/30124941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/key245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|